Concluding remarks.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 60, doi. 10.1093/rheumatology/39.suppl_2.60
- By:
- Publication type:
- Article
Works matching IS 14620324 AND DT 2000 AND VI 39 AND IP suppl_2
Results: 10
1
2
Discussion.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 57, doi. 10.1093/rheumatology/39.suppl_2.57
- Publication type:
- Article
3
The Swedish ACCES model.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 51, doi. 10.1093/rheumatology/39.suppl_2.51
- By:
- Publication type:
- Article
4
Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 43, doi. 10.1093/rheumatology/39.suppl_2.43
- By:
- Publication type:
- Article
5
Overview of the Arthritis Cost Consequence Evaluation System (ACCES).
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 33, doi. 10.1093/rheumatology/39.suppl_2.33
- By:
- Publication type:
- Article
6
Health economic models.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 29, doi. 10.1093/rheumatology/39.suppl_2.29
- By:
- Publication type:
- Article
7
Celecoxib clinical profile.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 21, doi. 10.1093/rheumatology/39.suppl_2.21
- By:
- Publication type:
- Article
8
Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 13, doi. 10.1093/rheumatology/39.suppl_2.13
- By:
- Publication type:
- Article
9
Epidemiology of rheumatic diseases.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 3, doi. 10.1093/rheumatology/39.suppl_2.3
- By:
- Publication type:
- Article
10
Introduction.
- Published in:
- Rheumatology, 2000, v. 39, n. suppl_2, p. 1, doi. 10.1093/rheumatology/39.suppl_2.1
- By:
- Publication type:
- Article